Thor Medical ASA Logo

Thor Medical ASA

Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.

NANOV | OL

Overview

Corporate Details

ISIN(s):
NO0010597883 (+1 more)
LEI:
5967007LIEEXZXG6DK30
Country:
Norway
Address:
Drammensveien 167, 0277 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Thor Medical ASA is an emerging producer and supplier of radionuclides for medical use, specializing in alpha-particle emitters for targeted alpha therapies in oncology. The company has developed a proprietary technology for manufacturing these isotopes by separating naturally occurring radioactive decay products from thorium. This novel process eliminates the need for nuclear reactors or cyclotrons, providing a more efficient, cost-competitive, and environmentally sustainable alternative to traditional production methods.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: 202…
Norwegian 93.5 KB
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: 202…
Norwegian 93.0 KB
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: Dow…
Norwegian 50.5 KB
2025-11-11 23:15
Remuneration Information
Thor Medical - Issuance of RSU shares to members of the board
English 2.5 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 56.4 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 6.2 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 50.3 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 2.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228 - …
English 64.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228
English 7.7 KB
2025-08-01 08:58
Declaration of Voting Results & Voting Rights Announcements
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 46.1 KB
2025-08-01 08:58
Share Issue/Capital Change
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 2.0 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering - Attachment: Downlo…
Norwegian 59.1 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering
Norwegian 10.1 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
Norwegian 62.0 KB

Automate Your Workflow. Get a real-time feed of all Thor Medical ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Thor Medical ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Thor Medical ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America
GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom
HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.